- MapLight dives despite positive data for schizophrenia drug<figure><div><img src="https://imgproxy.divecdn.com/hE3SUiWFPTXu78esitpkGlFwKNqX19ie92vbcO82d5g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDQ5MjI0OTcwXzIua…BioPharma Dive · 39m ago↗ source
- Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug<figure><div><img src="https://imgproxy.divecdn.com/nnTWCzHBd9_O2uNBVPF6xmxcO0M-nRFDpca5z-2Xchs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDMwNzQzODA0LmpwZ…BioPharma Dive · 1h ago↗ source
- Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pillPlus news about Outlook Therapeutics, Gossamer Bio, Apnimed and Entera Bio. 📈 Yarrow closes merger to go public: Yarrow Bioscience is developing an anti-TSHR antibody for Graves’ disease and thy…